- Home
- NVNO vs LGVN Comparison
NVNO vs LGVN Comparison
Compare NVNO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- LGVN
- Stock Information
- Founded
- NVNO 1987
- LGVN 2014
- Country
- NVNO United States
- LGVN United States
- Employees
- NVNO N/A
- LGVN N/A
- Industry
- NVNO Medical/Dental Instruments
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- NVNO Health Care
- LGVN Health Care
- Exchange
- NVNO Nasdaq
- LGVN Nasdaq
- Market Cap
- NVNO 42.7M
- LGVN 41.5M
- IPO Year
- NVNO N/A
- LGVN 2021
- Fundamental
- Price
- NVNO $3.23
- LGVN $1.85
- Analyst Decision
- NVNO
- LGVN Strong Buy
- Analyst Count
- NVNO 0
- LGVN 2
- Target Price
- NVNO N/A
- LGVN $8.00
- AVG Volume (30 Days)
- NVNO 231.7K
- LGVN 435.0K
- Earning Date
- NVNO 10-24-2024
- LGVN 11-08-2024
- Dividend Yield
- NVNO N/A
- LGVN N/A
- EPS Growth
- NVNO N/A
- LGVN N/A
- EPS
- NVNO N/A
- LGVN N/A
- Revenue
- NVNO N/A
- LGVN $1,229,000.00
- Revenue This Year
- NVNO N/A
- LGVN $161.78
- Revenue Next Year
- NVNO N/A
- LGVN $8.62
- P/E Ratio
- NVNO N/A
- LGVN N/A
- Revenue Growth
- NVNO N/A
- LGVN 39.34
- 52 Week Low
- NVNO $3.06
- LGVN $0.77
- 52 Week High
- NVNO $6.97
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- NVNO 20.88
- LGVN 37.39
- Support Level
- NVNO $3.06
- LGVN $1.92
- Resistance Level
- NVNO $3.37
- LGVN $2.05
- Average True Range (ATR)
- NVNO 0.27
- LGVN 0.10
- MACD
- NVNO -0.17
- LGVN 0.00
- Stochastic Oscillator
- NVNO 6.94
- LGVN 18.75
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.